

Koninklijke DSM N.V.  
 Form 3  
 July 17, 2017

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |          |                                      |  |  |  |
|---|---------|----------|--------------------------------------|--|--|--|
| 1. Name and Address of Reporting Person * |         |          | 2. Date of Event Requiring Statement |  | 3. Issuer Name and Ticker or Trading Symbol                |  |
| Â DSM International B.V.                  |         |          | (Month/Day/Year)                     |  | AMYRIS, INC. [AMRS]  |  |
| (Last)                                    | (First) | (Middle) | 07/07/2017                           |  | 4. Relationship of Reporting Person(s) to Issuer           |  |
| HET OVERLOON 1                            |         |          |                                      |  | 5. If Amendment, Date Original Filed(Month/Day/Year)       |  |
| (Street)                                  |         |          |                                      |  | (Check all applicable)                                     |  |
| HEERLEN,Â P7Â 6411 TE                     |         |          |                                      |  | 6. Individual or Joint/Group Filing(Check Applicable Line) |  |
| (City)                                    | (State) | (Zip)    |                                      |  | ___ Form filed by One Reporting Person                     |  |
|   |         |          |                                      |  | _X_ Form filed by More than One Reporting Person           |  |

**Table I - Non-Derivative Securities Beneficially Owned**

|                                 |   |  |   |
|---------------------------------|---|--|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

|  |  |   |  |  |   |
|--|--|---|--|--|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|  | Date Exercisable      Expiration Date                    | Title      Amount or Number of Shares                                       |  |  |   |

Edgar Filing: Koninklijke DSM N.V. - Form 3

|                          |            |            |              |           |         |   |                  |
|--------------------------|------------|------------|--------------|-----------|---------|---|------------------|
| Series B Preferred Stock | Â (1)      | Â (1)      | Common Stock | 3,968,116 | \$ (1)  | I | See footnote (2) |
| Warrants (right to buy)  | 07/07/2017 | 07/07/2022 | Common Stock | 1,984,058 | \$ 0.52 | I | See footnote (2) |
| Warrants (right to buy)  | 07/07/2017 | 07/07/2022 | Common Stock | 1,984,058 | \$ 0.62 | I | See footnote (2) |

## Reporting Owners

| Reporting Owner Name / Address                                  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| DSM International B.V.<br>HET OVERLOON 1<br>HEERLEN, P7 6411 TE | Â             | Â         | Â       | Â     |
| Koninklijke DSM N.V.<br>HET OVERLOON 1<br>HEERLEN, P7 6411 TE   | Â             | Â         | Â       | Â     |

## Signatures

|   |            |
|---|------------|
| DSM International B.V. By: /s/ Hugh Welsh, President, DSM North America | 07/17/2017 |
| __Signature of Reporting Person   | Date       |
| Koninklijke DSM N.V. By: /s/ Hugh Welsh, President, DSM North America   | 07/17/2017 |
| __Signature of Reporting Person   | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of Series B preferred stock is convertible at any time at the option of the holder into Common Stock of the Issuer on an approximately 1-to-158.7 basis. The Series B preferred stock has no expiration date.
- (2) The securities reported herein are held of record by DSM International B.V., which is a wholly owned subsidiary of Koninklijke DSM N.V. Accordingly, Koninklijke DSM N.V. may be deemed to share beneficial ownership of the securities held of record by DSM International. Koninklijke DSM N.V. is a publicly traded company with securities listed on the Amsterdam Stock Exchange.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.